Accounts Payable and Accrued Liabilities (Tables)

9 Months Ended

Sep. 30, 2025

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities consist of the following (in thousands):


			As of
			September 30, 2025						December 31, 2024
Accounts payable and other accrued operating expenses			$	79,591					$	73,033
Accrued clinical trial expenses			30,730						26,068
Accrued professional fees			25,776						17,895
Accrued technical operation expenses			20,227						18,388

Accrued compensation and employee related costs			69,712						80,312
Accrued royalty and milestones payable			9,372						6,324
Accrued interest payable			—						359
Revenue Interest Payments payable			4,941						4,177
Accrued sales allowances and related costs			33,026						16,762
Accrued French rebate payable			10,049						5,988
Contingent consideration			42,500						24,700
Development milestone shares issuable			48,753						—

Accrued milestone payment to AstraZeneca			30,000						—
Other accrued liabilities			5,158						11,203
			$	409,835					$	285,209